Elektrofi

Curated by Signal

Developer of a technology platform to design protein formulations

Overview

Developer of a technology platform to design protein formulations. The proprietary desiccation process is used to create high-concentration, low-viscosity protein formulations can be administered in small volumes via subcutaneous injection. It deevelops a range of therapeutic molecules which includes monoclonal antibodies, bispecifics and fusion proteins.

Key facts

Founded: 2016
Headquarters: Boston, United States
Stage: Sign up to view
Industry: Life Sciences Technology

Business model

2 products and services: Sign up to view

Contact

Email: Sign up to view

Open roles

2 roles

Head of Financial Planning & Analysis
Boston, MA · On-site · Full-time
Head of Translational Development
Boston, MA · On-site · Full-time

More on Vanberra Signal

Members only

Business overviewCore metrics and financials PeopleLeadership and key people Similar companiesPeers and competitors Deep AnalysisAI-generated strategic report

Competitors & similar companies

More Life Sciences Technology companies

NatPro Pharmaceutical
Developer of chemotherapeutic drugs for the treatment of cancer
Life Sciences TechnologyBrookings, United States
Movi Medical
Wheelchairs for patient transportation
Life Sciences TechnologyBirmingham, United States
Atantares
Developer of precision medicines & smart diagnostic devices by fusing biochip and AI technologies
Life Sciences TechnologyCambridge, United States

About Elektrofi

What does Elektrofi do?

Developer of a technology platform to design protein formulations.

Where is Elektrofi headquartered?

Elektrofi is headquartered in Boston, United States.

When was Elektrofi founded?

Elektrofi was founded in 2016.

Which sector is Elektrofi in?

Elektrofi operates in Life Sciences Technology.

Who are Elektrofi's competitors?

Companies similar to Elektrofi include NatPro Pharmaceutical, Movi Medical, and Atantares.

Is Elektrofi hiring?

Yes. Elektrofi has 2 open roles listed on Vanberra Signal.